Tim Eden qualified in 1970 and following training positions in London, Portsmouth, the Isle of Wight, Edinburgh and Stanford University, California, was appointed as Consultant Clinical Haematologist at Bristol Children’s Hospital at the South West and Regional Blood Transfusion Service in 1979. He then returned to Edinburgh and was the first paediatric haematologist and oncologist there in 1982. He has subsequently held Chairs in paediatric oncology at St Bartholomew’s Hospital and Medical College London and at the University of Manchester. In 2005 he moved sideways to become the first Teenage Cancer Trust Chair in teenage and young adult cancer in Manchester and retired from that post in 2008. His clinical expertise is in the field of paediatric cancer, especially leukaemia and lymphoma and more recently, the malignancies of the TYA years. His research activity has included clinical trial creation, organisation and analysis; genetic epidemiology of childhood and adolescent malignancies; psycho-social functioning of children with cancer and their families; Cochrane reviews which create evidence based medicine; and the investigation of patient pathways and how they can be improved. He was President of the International Society of Paediatric Oncology (SIOP) from 2004 – 2007 and is a founding Trustee of World Child Cancer and AFROX, both organisations focus on supporting and providing sustainability funding to developing units in resource-limited countries. He remains a Medical Advisor to the Teenage Cancer Trust and is a Faculty Associate of the Brooks World Poverty Institute at the University of Manchester.

Tasneem Khalid is Principal Pharmacist - Haematology/Oncology at Royal Manchester Children's Hospital, Pendlebury, Manchester.

After receiving a brief introduction to paediatric oncology as a pre-registration pharmacist in Birmingham, Tasneem took up the position of Clinical Services Pharmacy Manager at Royal Manchester Children’s Hospital in 1995. This role involved numerous areas of responsibility in addition to the provision of the clinical pharmacy service to haematology/oncology patients. As time passed and her role developed in the clinical team, the post became that of Principal Pharmacist, Haematology/Oncology. From March 2001 to 2008 Tasneem chaired the Paediatric Oncology Pharmacists (POP) Group and amongst other things worked to establish a good working relationship with the Children’s Cancer and Leukaemia Group and became much more involved than before in the preparation of clinical trials, writing and advising on pharmaceutical matters. Other areas of work included early involvement with the Department of Health’s first National Guidance on the safe administration of intrathecal chemotherapy.

Angela Thomas is Consultant Paediatric Haematologist at the Royal Hospital for Sick Children in Edinburgh.

After qualifying in Medicine from the University of London in 1980, Angela  trained in general medicine and then adult haematology, subsequently developing a special interest in paediatrics. She was a fellow in molecular biology at University College London and was awarded a PhD on Genetic Variation of the Fibrinogen Gene.

Angela was appointed in 1992 as a consultant paediatric haematologist at the Royal Hospital for Sick Children in Edinburgh and is co-director of the Haemophilia Centre at the Edinburgh Royal Infirmary with specific responsibility for paediatrics. She cares for children with a wide range of haematological disorders, including those with leukaemia, immune deficiency, haemolytic anaemias and bleeding disorders. She has a special interest in the education of paediatricians in the varied presentation of haematological disease, particularly bleeding disorders presenting as possible non-accidental injury.

In addition to her clinical post, Angela is a member of the Commission for Human Medicines (CHM) and chairs its Biologicals and Vaccines Expert Advisory Group. The CHM advises on the quality, safety and efficacy of human medicinal products and advises the Licensing Authority on the granting of a licence for such products.

Riccardo Riccardi is Full Professor of Pediatrics at the Catholic University of Rome.

He is Director of the Department of Pediatrics and Head of the Division of Pediatric Oncology of Catholic University of Rome. He is an expert in the field of clinical pharmacology of antineoplastic drugs in children. In the past he spent three years at the Pediatric Oncology Branch of National Cancer Institute of Bethesda (USA) and he continued research activity in clinical pharmacology until now.

Professor Riccardi is:

Chairman of the “Clinical Pharmacology Committee” of the Italian Society of  Hematology and Oncology (AIEOP)
Chairman of the Educational and Training Committee of the International Society of Pediatric Oncology  Europe (SIOPE)
Co-chair of the European Society of Oncology - SIOPE Masterclass in Pediatric Oncology: Orta San Giulio (Novara, Italy), October 2006 and Ascona (Switzerland), November 2008;
Coordinator of “Clinical drug development: a post-graduate course for ITCC members”, Orta San Giulio (Novara, Italy), March 2008
and of “Training Days 2009: New Drugs Development in Paediatric Oncology”, Catholic University of Rome, October 2009;
Faculty member of the ECCO-AACR-ASCO Workshop “Methods in Clinical Cancer Research”, Flims (Switzerland), June 2008 and June 2009;
Member of the Executive Committe of the European Consortium ITCC (Innovative Therapies for Children with Cancer);
National coordinator for the following early clinical trials:
Phase I of Tarceva (Erlotinib Hydrochloride, OSI-774) as single Agent in Children with Refractory and Relapsed Malignant Brain Tumors and in Combination with Irradiation in Newly Diagnosed Malignant Brain Stem Glioma;
A Phase 2 Single-Arm Study of Gemcitabile in Combination with Oxaliplatin in Pediatric patients with Relapsed or Refractory neuroblastoma or Miscellaneous Solid Non-CNS Tumors;
Phase 2-single arm studies of Temozolomide in combination with Topotecan refractory and relapsed neuroblastoma and other pediatric solid tumours.

Louise Soanes is TCT Nurse Consultant for Adolescents and Young Adults at the Royal Marsden NHS Trust, Sutton, Surrey.

Her areas of medical interest and expertise are: Nursing, Cancer and Adolescents and Young Adults

Louise’s medical roles have included Co-Chair of the TYAC Service Development Group and Steering Group of the Paediatric Oncology Nurses Forum.

Kate Pye, R.N child, ENB 240 and 998, Bsc (Hons) Children’s nursing is currently completing her Masters at the University of the West of England in Advanced Practice.

Kate has been the Matron at the Royal Marsden since Jan 2009.Prior to this she was the Ward Manager in Bristol and has worked within the field of paediatric oncology nursing since 1994.  This experience includes working in three out of the previous four cancer centres in London, and also 3 years working in shared care at St Georges Hospital.  Kate is also a steering group member of PONF. 

Kate’s interests include the role of communication and the way that all members of the MDT work together. This led her to investigate doctor and nurse experiences of moral distress in paediatric oncology for her dissertation which she hopes to publish when completed. Kate also feels very strongly that the process of discharge and the experiences of this should be standardised for families and this is also going to be published soon in paediatric nursing. 

Dr Jan Kohler is a Paediatric Oncologist in Southampton.

Jan’s particular interest is in neuroblastoma and she is a member of the UK and European neuroblastoma working groups (chair UK group 1996-2001). She is on the Executive of the CCLG from 2005 to 2009 and is Chair of the Clinical Research Governance Group. Jan is also a member of the oncology education and training committee 2003-8.

Dr Hamish Wallace has been a Consultant Paediatric Oncologist at the Royal Hospital for Sick Children Edinburgh since 1992.  He is also Reader in the Department of Reproductive and Developmental Sciences at the University of Edinburgh.

Hamish qualified at St George’s Hospital Medical School in 1980 and trained in paediatric oncology at Great Ormond Street, as well as Birmingham and Edinburgh.           

Hamish was Leukaemia Research Fund Research Fellow under the guidance of Professor Shalet in Manchester in the late 1980s when he developed his research interest in the late endocrine effects of the treatment of childhood cancer.

Hamish is currently Chairman of the CCLG Hodgkin’s Lymphoma Working Group and President of the European Network for Paediatric Hodgkin’s Lymphoma.  He is Director of the HEBA Research Centre in Edinburgh which is committed to ongoing research into the effects of the treatment of childhood cancer on fertility, bone health and the vascular endothelium.  He is also co-author of over 100 peer reviewed publications, and four books.  Most recently he co-edited with Professor Dan Green a multi-author book on “Late effects of the treatment of Childhood Cancer” and with Professor Chris Kelnar a book on  “Endocrine complications of the treatment of childhood cancer”. Hamish was appointed in November 2007 as Lead Clinician for the Children’s and Young Peoples MCN for Cancer in Scotland “CATSCAN”.

Registration Cancellation Policy:
Cancellations should be made in writing to the Conference Secretariat.  E-Mail is acceptable.

• Cancellations received up to and including  31st March 2010: full refund minus 25% administration charge.
• Cancellation received from  1st April 2010: no refund.
• All approved refunds will be processed and issued 60 days after the Conference